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The clinical spectrum of anxiety ranges 
from a normal experience to a psychopatho-
logical state. Anxious patients usually pre-
sent with symptoms that can be divided into 
four major groups: 
1. Subjective feeling 
2. Cognitive disturbances 
3. Behavioural changes, and 
4. Somatic complaints 
Patients with anxiety experience loss of 
confidence in their daily activities with auto-
nomic hyperactivity and complaint of a pani-
cky state and difficulty in sleeping. How well 
the patient is able to cope with anxiety will 
delineate its exact clinical and pathological 
significance. It is estimated that anywhere 
from 5-10% of the population is afflicted with 
pathological anxiety. Maintenance of normal 
daily activities becomes difficult for such 
people and they over-react to stressful stimuli 
(Lapierre, 1984). 
A number of drugs are available for use as 
antianxiety agents. However, the selection of 
an appropriate agent will depend on the type 
of anxiety, its triggering event as well as the 
accompanying conditions. Modern drugs like 
benzodiazepines and propanediols are useful 
but must be cautiously prescribed due to their 
liability to cause drug dependence and side-
effects. 
Geriforte is an indigenous herbal prepara-
tion which has been shown to possess adapto-
genic and antistress effects in experimental 
studies. These findings have been also con-
firmed in some clinical situations. An attempt 
has been made to critically evaluate the anti-
anxiety effect of Geriforte in anxiety neurosis. 
MATERIAL AND METHODS 
It was an open controlled study of 30 male 
and female patients (mean age 43.93±1.25 
years), suffering from anxiety disorders with 
varying degrees of severity, for durations of 2 
months to 2 years. The diagnostic criteria for 
diagnosis was ICD-9 for anxiety neurosis and 
anxiety neurosis with depression (WHO, 
1978). They were already receiving other 
drugs like imipramine, diazepam, chlordiaze-
poxide, amitryptiline or doxepin. The drugs 
and their dosages were kept stable for at least 
six weeks before commencing Geriforte thera-
py. Only those patients, in whom the symp-
toms were not controlled inspite of adequate 
dosage of the other drugs, received Geriforte 
in the dose of two tablets three times a day 
for six weeks. 
The patients were followed up every week 
in the OPD to check improvement, if any, by 
using the Hamilton Anxiety Rating Scale 
(HARS). They were also asked to relate their 
own subjective impressions about the treat-
ment. The clinical impressions in the patients' 
status were also noted at the follow-up. Side-
effects, if any, were noted. 
RESULTS 
There was a mean reduction in the total 
score on the HARS (Table). Inspite of 
other drug therapy that these patients were 
receiving before Geriforte treatment, the ini-
tial total score was 29.27. The effect of Geri-
forte was observed by the third week and there 
was significant reduction in the total score 
at the end of the fifth and sixth weeks of the-
rapy (Fig.). 
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TABLE. Mean total score in anxiety and anxiety with 
depression before and after Geriforte 
Anxiety 
(n-22) 
Anxiety with 
Depression (n=  =8) 
1st week 
29.27* 
±1.27 
30.29* 
±1.30 
*P< O.OOl 
6th week 
22.19* 
±0.86 
21.86* 
±1.14 
n=number of patients 
Patients experienced both subjective and 
objective improvements. Subjectively the pa-
tients reported a feeling of well-being and a 
soothing, quietening effect on the mind. They 
did not have any feeling of being sedated. The 
capacity to carry out day-to-day activity also 
improved. Clinically also, the patients showed 
improvement. 
Statistical analysis (Signed rank sum test) 
to check the effect of Geriforte in males and 
females showed that both groups showed 
equal improvement. Incidentally, there were 
more males than females in our study, but 
the degree of anxiety, to start with, in both 
the groups was the same. 
The data was also analysed to assess the 
difference, if any, in the two age groups of 
patients, i.e. one group below 40 years of age 
and the other above 40. There were more 
patients suffering from anxiety in the group 
aged above 40 years. The severity of the con-
dition was slightly more in the younger age 
group. But the degree of improvement in 
both the groups was about the same. 
There were 22 cases suffering from anxiety, 
and 8 with anxiety plus depression (Table). 
Once again the degree of improvement follow-
ing Geriforte treatment was the same in both 
the groups. Geriforte seemed to help in re-
ducing anxiety as well as depression. 
The data was analysed separately to check 
the trend in improvement following Geri-
forte treatment in 14 parameters of the HARS. 
It was seen that the initial score was high in 
5 parameters, viz. anxious mood, tension, car-
diovascular symptoms, fear and insomnia. 
Improvement was evident in relief from an-260 G. C. BO 
xiousmood, tension and cardiovascular symp-
toms. Marked improvement was noted in be-
haviour at the interview. As far as the other 
parameters are concerned, improvement was 
also noted but it was less marked. 
Side-effects 
No side-effects were reported or observed 
during the course of Geriforte therapy. On 
the contrary, a feeling of well-being was re-
ported by almost all the patients. 
DISCUSSION 
Severe anxiety, whether primary or se-
condary, can be very disabling and the aim 
of treatment is to alleviate the symptoms and 
reduce them to a tolerable level. None of the 
drugs available today meets the requirements 
o£ an ideal anti-anxiety agent although the 
benzodiazepines are very close to it (Rickels, 
1978). 
Using more than one anxiolytic agent may 
not be therapeutically very advantageous if 
the mechanism of action of these agents re-
mains the same (Hollister, 1972). 
The beneficial effect oC Geriforte, when 
combined with other agents, is most probably 
due to the different modes of action resulting 
in synergy. 
. ET AL. 
It was surprising to observe that more 
patients above the age group of 40 had the 
symptoms of anxiety. The number of aged 
people in the world is rapidly rising and so 
also the stressful conditions. It would be 
worthwhile to have the observations from 
other urban parts of India. 
The present study has not only established 
the beneficial effect of Geriforte in anxiety 
neurosis but also shown that Geriforte offers 
promise as a good addition to ongoing the-
rapy in such patients. 
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